“What’s New Doc?” in GU Cancer
Join us for insightful updates on the forefront of genitourinary (GU) cancer research with our new series, “What’s New Doc?” in GU Cancer. Each week, experts in the field will share comprehensive information and provide fresh perspectives on the latest data, offering valuable insights into GU cancer treatment and research.
Explore a diverse range of cutting-edge communication as we bring you the most recent advancements in GU cancer research. Stay tuned for weekly updates that promise to enhance your understanding of the evolving landscape in GU cancer treatment.
In this new episode of WND Prostate cancer, Prof Bertrand Tombal from the Cliniques Universitaires Saint-Luc in Brussels and Prof Steven Joniau from the University Hospitals Leuven share their thoughts on the results of the phase III PROpel study, a
In this first episode of WND Prostate cancer, Prof Bertrand Tombal from the Cliniques Universitaires Saint-Luc in Brussels and Prof Steven Joniau from the University Hospitals Leuven share their thoughts on the results of the phase III EMBARK trial.
In EMBARK,
In this episode of ‘What’s New Doc’ in GU cancer, Prof Emmanuel Seront from UCL Louvain and Prof Christof Vulsteke from Maria Middelares Gent will discuss the THOR trial, focusing on two cohorts of metastatic urothelial carcinoma patients with FGFR
In this episode of ‘What’s New Doc’ in GU cancer, Prof Emmanuel Seront from UCL Louvain and Prof Christof Vulsteke from Maria Middelares Gent will discuss the findings of belzutifan in metastatic ccRCC, as conducted in the LITESPARK-005 study.
In
How does the NEMIO trial improve neoadjuvant chemotherapy in the perioperative setting in MIBC patients? In these cases, cisplatin-gemcitabine-based chemotherapy is SOC. However, given the correlation between higher pCR rates and improved outcomes, various approaches are being explored alongside ddMVAC.
The widely recognized enfortumab vedotin (EV), which targets nectin-4, was paired with sacituzumab govitecan (SG), targeting Trop-2. This approach aims to address two distinct targets with separate payloads and non-overlapping toxicities.
The trial focused on assessing the safety and efficacy
In metastatic renal cell cancer (mRCC), immune checkpoint inhibitors (ICI) are SOC in first-line treatment, either in combination with IO-IO or IO-TKI. Following the progression after ICI, treatment options are limited to single agents like the TKI cabozantinib. The CONTACT-03
In this episode of WND, Prof Emmanuel Seront from UCL Louvain and Prof Vulsteke from Maria Middelares Gent are engaged in a discussion regarding a recent phase 2 study that adds checkpoint inhibition to chemoradiation for the treatment of muscle-invasive
Prof Emmanuel Seront from UCL Louvain and Prof Vulsteke from Maria Middelares Gent are engaged in a discussion centred on the THOR-2 trial, which investigates targeted therapy for high-risk non–muscle-invasive bladder cancer (HR NMIBC).
In cohort 1 of the study, patients
The regimen which combines lenvatinib with pembrolizumab, has become well-established in medical oncology as a treatment for endometrial cancer. This combination also demonstrated efficacy in clear cell renal cancer, leading to its recent reimbursement in that context due to a
Prof Vulsteke from Maria Middelares Gent will present the CheckMate901 study, presented at ESMO2023. In this trial, SOC cisplatin chemotherapy was combined with nivolumab for the first-line treatment of metastatic urothelial cell cancer. CheckMate901 marked the first positive trial in
Professor Vulsteke from Maria Middelares Gent will discuss the SunRISE-1 study, presented at ESMO2023. This study is centred on NMIBC, diverging from the typical purview of urologists, as it excludes metastatic urogenital cancer and perioperative conditions.
The SunRISE-1 trial employs